EMERGENT BIOSOLUTIONS INC. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2015-03-09
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2013-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2013-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2013-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2013-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2014 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2012 was $1.97M, a 53.74% decline from fiscal 2011.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2011 was $4.25M, a 34.80% decline from fiscal 2010.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-09 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 10-K · filed 2015-03-09 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $0.00 10-Q · filed 2013-08-06 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-03 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $1.97M 10-K · filed 2015-03-09 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $1.97M 10-Q · filed 2013-11-08 | $2.47M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $1.97M 10-Q · filed 2013-08-06 | $2.47M derived: sum of 3 quarters · filed 2014-03-10 | $3.97M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-03-31 | $1.97M 10-Q · filed 2013-05-03 | $2.47M derived: sum of 2 quarters · filed 2014-03-10 | $3.97M derived: sum of 3 quarters · filed 2014-03-10 | $6.22M derived: sum of 4 quarters · filed 2014-03-10 |
| 2011-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $2.00M derived: sum of 2 quarters · filed 2014-03-10 | $4.25M derived: sum of 3 quarters · filed 2014-03-10 | $4.25M 10-K · filed 2014-03-10 |
| 2011-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $3.75M derived: sum of 2 quarters · filed 2012-11-01 | $3.75M 10-Q · filed 2012-11-01 | $10.27M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $2.25M 10-Q · filed 2012-08-03 | $8.77M derived: sum of 3 quarters · filed 2013-03-08 | $8.77M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-03-31 | $0.00 10-Q · filed 2012-05-04 | $6.52M derived: sum of 2 quarters · filed 2013-03-08 | $6.52M derived: sum of 3 quarters · filed 2013-03-08 | |
| 2010-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $6.52M derived: sum of 2 quarters · filed 2013-03-08 | $6.52M 10-K · filed 2013-03-08 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $0.00 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |